METHOD FOR PREDICTION OF HAEMATOGENIC METASTASIS IN BREAST CANCER PATIENTS AFTER ANTICANCER TREATMENT Russian patent published in 2011 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention describes a method for prediction of haematogenic metastasis to remote organs in breast cancer (BC) patients after anticancer treatment by determining blood values, namely immune system values in diagnosing during anticancer treatment and after termination thereof: peripheral blood CD4⁺ cell count, %, peripheral blood CD8⁺ cell count, %, peripheral blood CD56 cell count, %, peripheral blood CD22⁺ cell count, %, peripheral blood CD95⁺ cell count, %, a functional neutrophil reserve in nitro blue tetrazolium reduction test, standard units, functional neutrophil reserve in nitro blue tetrazolium reduction test, %, spontaneous neutrophil activity in nitro blue tetrazolium reduction test, standard units, spontaneous neutrophil activity in nitro blue tetrazolium reduction test, %, circulating immune complex level, standard units, blood serum immunoglobulin G (IgG) level, g/l, blood serum IgM level, g/l, blood serum IgA level, g/l, immunoregulatory index (CD4⁺/CD8⁺), level of spontaneous tumour necrosis factor α production (TNFα) by peripheral blood cells, pg/ml, level of spontaneous intreleukin-1β (IL-1β) production by peripheral blood cells, pg/ml, level of stimulated IL-1β production by peripheral blood cells, pg/ml, peripheral blood CD3⁺ cells count, %, activity of blood serum complement system, standard units, peripheral blood CD25⁺ cells count, %, a phytohemagglutinin stimulated lymphocyte proliferation index, phytohemagglutinin stimulated proliferative lymphocyte activity, spontaneous proliferative lymphocyte activity, level of peripheral blood cells with morphological apoptosis signs, %; discriminant functions Y₁, Y₂ are calculated by discriminant equations related to each follow-up stage; a classified case is referred to that class of prognosis for which a greater value of the calculated discriminant function is obtained.

EFFECT: method allows providing higher prediction accuracy and information value of haematogenic metastasis in the BC patients exposed to combined anticancer treatment for 3 years after diagnosing.

4 ex, 14 tbl, 1 dwg